1453167-99-1

Basic information

• Product Name: ent-14S-3-Methoxy-17-MethylMorphinan
• Synonyms: ent-14S-3-Methoxy-17-MethylMorphinan;Morphinan, 3-Methoxy-17-Methyl-, (9a,13a)-;Dextromethorphan EP Impurity D;(4bS,8aR,9S)-3-methoxy-11-methyl-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene
• CAS NO: 1453167-99-1
• Molecular Formula: C18H25NO
• Molecular Weight: 271.3972
• Mol File: 1453167-99-1.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 394.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• PKA: 9.13±0.20(Predicted)
• CAS DataBase Reference: ent-14S-3-Methoxy-17-MethylMorphinan(CAS DataBase Reference)
• NIST Chemistry Reference: ent-14S-3-Methoxy-17-MethylMorphinan(1453167-99-1)
• EPA Substance Registry System: ent-14S-3-Methoxy-17-MethylMorphinan(1453167-99-1)

Safety Data

• Hazardous Substances Data: 1453167-99-1(Hazardous Substances Data)

Usage

Uses

(9α,13α)-3-Methoxy-17-methylmorphinan is an analog of Dextromethorphan (D299445) which is an antitussive compound showing analgesic properties. Dextromethorphan is used in cough medication formulations.

Upstream product

• 38969-65-2 1-(p-methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 98237-33-3 1-(4-Methoxybenzyl)-2-methyl-5,6,7,8-tetrahydroisochinoliniumiodide 
• 186581-53-3 diazomethane 
• 888939-18-2 3-Hydroxy-N-methylmorphinan 
• 77-07-6 racemorphan 
• 51072-36-7 (+)-1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 1899-02-1 trimethylphenylammonium hydroxide 
• 67596-84-3 (+)-2-methyl-1-(4-methoxy)benzyl-1,2,3,4,5,6,7,8-hexahydroisoquinoline 
• 6700-34-1 dextromethorphan hydrobromide, monohydrate 
• 113951-04-5 dextromethorphan N-oxide hydrochloride 
• 3399-73-3 2-(1-cyclohexenyl)ethylamine 
• 29144-31-8 (S)-2-Formyl-1-<(4-methoxyphenyl)methyl>-1,2,3,4,5,6,7,8-octahydroispquinoline 
• 116172-20-4 (Z)-2-Formyl-1-<(4-methoxyphenyl)methylene>-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 51072-34-5 N-(2-cyclohex-1-enylethyl)-2-(4-methoxyphenyl)-acetamide 

Downstream Products

• 18050-88-9 3-methoxy-10-keto-N-methylmorphinan 
• 121292-34-0 ent-(17Ξ)-17-benzyl-3-methoxy-17-methyl-morphinanium; bromide 
• 57969-05-8 (9α,13α,14α)-3-methoxy-17-methylmorphinan-10-one 
• 113951-05-6 dextromethorphan N-oxide 
• 113951-05-6 rac-(17Ξ)-3-methoxy-17-methyl-morphinane-17-oxide 
• 118982-15-3 ent-17-benzyl-3-methoxy-17-methyl-9,10-didehydro-9,17-seco-morphinane 
• 1531-23-3 (4bR,9R)-3-methoxy-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene 
• 1079043-55-2 [2H]-Dextromethorphan 3,17-d6 
• 36304-81-1 Dimemorfan 
• 1531-23-3 3-methoxymorphinan 
• 1079043-47-2 (4bS,8aS,9S)-ethyl 3-hydroxy-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene-11-carboxylate 
• 524713-56-2 N-CD3-dextromethorphan 
• 18609-21-7 Dextromethorphan hydrochloride 
• 53447-08-8 [18,18,18-2H₃]-6-hydroxy-17-methyl-morphinan 

Relevant articles and documents

METHODS FOR PREPARING LEVORPHANOL AND RELATED COMPOUNDS, AND COMPOSITIONS THEREOF

A method for producing substantially pure levorphanol and related compounds, when compared to the conventional process, is provided. In particular, a method for producing substantially pure levorphanol tartrate dihydrate is described. Also described are compositions comprising levorphanol and related compounds, particularly compositions comprising levorphanol tartrate dihydrate, levomethorphan, and norlevorphanol in which the levomethorphan and norlevorphanol are present in the composition in reduced levels.

DEUTERATED MORPHINAN COMPOUNDS FOR USE IN TREATING AGITATION

This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.

COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY

Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.